VSee Health (VSEE) director receives multiple stock awards for service

Q: Who is the insider reporting this Form 4 for VSee Health (VSEE)?

The reporting person is Cydonii V. Fairfax , who serves as a director of VSee Health, Inc. and is not listed as an officer or 10% owner.

Q: What type of transactions did the VSee Health (VSEE) director report?

All reported transactions are acquisitions (code A) of VSee Health common stock, reflecting stock awards rather than open-market purchases or sales.

Q: What is the source of the stock awards reported by the VSee Health (VSEE) director?

Each award reflects shares issued under VSee Health’s 2024 Incentive Plan in line with the non-employee director compensation policy for board service.

Q: At what prices were the VSee Health (VSEE) director stock awards valued?

Grant-date prices per share include $0.69 , $1.16 , $1.20 , $1.36 , and $1.49 , based on the closing price of VSee Health common stock on the specified dates in the footnotes.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

VSee Health, Inc. director Cydonii V. Fairfax reported multiple stock awards of common shares on September 19, 2025. Each award is coded as an acquisition, reflecting stock granted under the company’s 2024 Incentive Plan as part of the non-employee director compensation policy.

The reported grants cover service as a director for quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024, with grant-date prices ranging from $0.69 to $1.49 per share. After the most recent reported award of 21,870 shares at $0.69 per share, Fairfax directly holds 68,397 shares of VSee Health common stock.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider FAIRFAX CYDONII V.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, par value $0.0001 per share	21,870	$0.69	$15K
Grant/Award	Common Stock, par value $0.0001 per share	12,931	$1.16	$15K
Grant/Award	Common Stock, par value $0.0001 per share	12,500	$1.20	$15K
Grant/Award	Common Stock, par value $0.0001 per share	11,029	$1.36	$15K
Grant/Award	Common Stock, par value $0.0001 per share	10,067	$1.49	$15K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 68,397 shares (Direct)

Footnotes (1)

Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on September 22, 2025. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended June 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on June 30, 2025. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended March 31, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on March 31, 2025. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended December 31, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on December 31, 2024. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on September 30, 2024.

Form 4 Insider Transactions: What Each Field Means →

01/16/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FAIRFAX CYDONII V.

(Last)

(First)

(Middle)

C/O VSEE HEALTH, INC.

980 N FEDERAL HWY #304

(Street)

BOCA RATON

33432

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VSEE HEALTH, INC. [ VSEE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.0001 per share	09/19/2025		A		21,870	A	$0.69⁽¹⁾	68,397	D
Common Stock, par value $0.0001 per share	09/19/2025		A		12,931	A	$1.16⁽²⁾	46,527	D
Common Stock, par value $0.0001 per share	09/19/2025		A		12,500	A	$1.2⁽³⁾	33,596	D
Common Stock, par value $0.0001 per share	09/19/2025		A		11,029	A	$1.36⁽⁴⁾	21,096	D
Common Stock, par value $0.0001 per share	09/19/2025		A		10,067	A	$1.49⁽⁵⁾	10,067	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on September 22, 2025.

2. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended June 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on June 30, 2025.

3. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended March 31, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on March 31, 2025.

4. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended December 31, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on December 31, 2024.

5. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on September 30, 2024.

	/s/ Cydonii V. Fairfax	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider reporting this Form 4 for VSee Health (VSEE)?

The reporting person is Cydonii V. Fairfax, who serves as a director of VSee Health, Inc. and is not listed as an officer or 10% owner.

What type of transactions did the VSee Health (VSEE) director report?

All reported transactions are acquisitions (code A) of VSee Health common stock, reflecting stock awards rather than open-market purchases or sales.

How many VSee Health (VSEE) shares does the director hold after these awards?

Following the most recent reported stock award of 21,870 shares at $0.69 per share, Cydonii V. Fairfax directly holds 68,397 shares of VSee Health common stock.

What is the source of the stock awards reported by the VSee Health (VSEE) director?

Each award reflects shares issued under VSee Health’s 2024 Incentive Plan in line with the non-employee director compensation policy for board service.

Which service periods do these VSee Health (VSEE) stock awards cover?

The footnotes state the awards cover director service for quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024.

At what prices were the VSee Health (VSEE) director stock awards valued?

Grant-date prices per share include $0.69, $1.16, $1.20, $1.36, and $1.49, based on the closing price of VSee Health common stock on the specified dates in the footnotes.